Overactive Bladder Clinical Trial
Official title:
"The Effects of Caffeine on Overactive Bladder Symptoms and Mental Health in Postmenopausal Women"
The purpose of this study is to observe effects of caffeine on overactive bladder symptoms
and wellbeing. This study looks at whether caffeine has bad effects on urinary symptoms or if
lower doses of caffeine decrease the effects.
The study will propose the following hypothesis:
1. The voiding and mental health symptoms will be greatest in the high dose treatment and
lowest in the placebo treatment.
2. The low dose treatment will produce more voiding and mental health symptoms than the
placebo treatment.
3. Voiding and mental health symptoms will be mediated by hydration status of the patient
which will be assessed using a Tanita Scale.
Subjects will be exposed to 200 mg and 400 mg caffeine pills and placebo pills (free of
caffeine). During each treatment period, participants will be required to avoid caffeine
(except for the caffeine within the given treatment). The study is staged into 3 phases,
which will last for 7 days each. After enrollment, participants will be asked to refrain from
consuming any substances containing caffeine during the 21 days of treatment. Instead of
coffee or other caffeine items, they will be exposed to caffeine in pill form. Participants
will complete each treatment in a random, cross over blinded fashion. One phase of treatment
will have participants consume two 200 mg-caffeine pills a day (total of 400 mg of
caffeine/day), a second treatment will have participants consume one 200 mg-caffeine pill and
one placebo pill a day. And the final treatment will have participants consume two placebo
pills each day. Treatment phases will be assigned randomly to each participant. The
participant will not know which phase they are receiving.
Prior to the treatment, the participant will be asked to fill out a detailed diet log of her
eating and drinking habits. Participants will also be asked a series of questions on a survey
related to bladder symptoms and mental health periodically throughout the study. It will take
about 30 minutes of their time to answer the questionnaires at individual time points.
During the 21 days of the study period participants will be asked to self-monitor fluid
intake and note any major changes of fluid intake compared to the initial intake log. They
will be asked to conduct a 24-hour voiding and defecation log at two different time points
within each treatment phase as well as prior to the study. 24-hour urine will be collected
during each treatment phase at two different time points as well as prior to the study.
Participants weight and lean body mass will be assessed in clinic using a Tanita scale at two
times within each treatment phase and one time prior to the study
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04578899 -
"The Effectiveness of Transvertebral Magnetic Neuromodulation in Patients With Detrusor Overactivity"
|
N/A | |
Active, not recruiting |
NCT03556891 -
Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence
|
N/A | |
Not yet recruiting |
NCT05977634 -
Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder
|
N/A | |
Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
Recruiting |
NCT06201013 -
Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children
|
N/A | |
Recruiting |
NCT03727711 -
TPTNS: Home vs Hospital Treatment for Overactive Bladder
|
N/A | |
Completed |
NCT00768521 -
A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)
|
Phase 1 | |
Completed |
NCT03625843 -
Mindfulness Exercises to Reduce Anxiety and Pain During Urodynamic Testing
|
N/A | |
Completed |
NCT02211846 -
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder
|
Phase 1 | |
Completed |
NCT02857816 -
PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB
|
N/A | |
Completed |
NCT02835846 -
Investigation of the Effect of the Female Urinary Microbiome on Incontinence
|
Phase 4 | |
Withdrawn |
NCT02320201 -
Foot Neuromodulation for Overactive Bladder in Children
|
N/A | |
Completed |
NCT02202031 -
Controlling Urgency Through Relaxation Exercises
|
N/A | |
Not yet recruiting |
NCT01423838 -
Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder
|
Phase 4 | |
Completed |
NCT01437670 -
Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin
|
N/A | |
Completed |
NCT01458197 -
A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.
|
Phase 2 | |
Not yet recruiting |
NCT01409512 -
Evaluation of Autonomic System Before and After Anticholinergic Treatment in Women With Overactive Bladder
|
N/A | |
Withdrawn |
NCT01210859 -
Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents
|
N/A | |
Terminated |
NCT01758848 -
Physical Therapy for Overactive Bladder
|
N/A | |
Completed |
NCT01122550 -
Reproducibility Study of Overactive Bladder Symptom Score [OABSS]
|
N/A |